Somewhat Favorable News Coverage Somewhat Unlikely to Affect Syros Pharmaceuticals (SYRS) Share Price
Headlines about Syros Pharmaceuticals (NASDAQ:SYRS) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.4036260427352 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Critical Review: Cardiome Pharma Corporation (CRME) vs. Syros Pharmaceuticals (SYRS) (americanbankingnews.com)
- Syros Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SYRS) : November 2, 2017 (finance.yahoo.com)
- Reviewing Syros Pharmaceuticals (SYRS) & Biogen (BIIB) (americanbankingnews.com)
- Syros Pharmaceuticals (SYRS) to Results from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH (streetinsider.com)
- Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 1, 2017 (finance.yahoo.com)
Shares of Syros Pharmaceuticals (SYRS) traded up $0.25 on Friday, hitting $12.90. The stock had a trading volume of 182,011 shares, compared to its average volume of 143,368. Syros Pharmaceuticals has a 12-month low of $10.22 and a 12-month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. sell-side analysts forecast that Syros Pharmaceuticals will post -2.09 earnings per share for the current year.
Several research analysts have commented on SYRS shares. Cann restated a “buy” rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, JMP Securities downgraded Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $26.14.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Syros Pharmaceuticals (SYRS) Share Price” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-syros-pharmaceuticals-syrs-share-price/1681520.html.
In related news, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $22.00, for a total transaction of $72,204.00. Following the transaction, the director now directly owns 420,101 shares of the company’s stock, valued at approximately $9,242,222. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric R. Olson sold 2,500 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the transaction, the insider now directly owns 2,500 shares in the company, valued at $58,975. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,332 shares of company stock valued at $140,012. Corporate insiders own 33.60% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.